Cicolin

Quick links to important sections

Cicolin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cicolin

Property Description
Active Ingredient Citicoline (Cytidine 5'-diphosphocholine)
Form Tablet, oral solution, solution for injection
Pharmacological Class Nootropic Agent / CNS Agent
General Purpose Support cognitive function and neuronal repair
Origin Synthetic, identical to an endogenous metabolite

Cicolin: Identity, Class, and Composition

Cicolin is a medication primarily classified as a Nootropic Agent and a Central Nervous System (CNS) Agent, designed to support the structural health and function of nerve cells. The core active compound is Citicoline, which is chemically defined as Cytidine 5'-diphosphocholine (CDP-choline). This substance is widely recognized in neurological pharmacology for its structural role. Cicolin is a common trade name for preparations containing Citicoline, which is often available as a prescription-only medicine in its injectable form, differentiating it from over-the-counter choline supplements. It is supplied in various pharmaceutical preparations, including a tablet, an oral solution, and a solution for injection, accommodating both oral and parenteral routes of administration.

Origin and General Purpose of the Drug

The active compound, Citicoline, is a synthetic substance chemically identical to an endogenous metabolite found naturally within the human body. Its function is crucial as it provides direct precursors for the synthesis of phosphatidylcholine, an essential component of the brain's cellular membranes. Functioning as a neuroprotective agent, its utility is clinically recognized in contexts requiring support for brain repair and metabolic efficiency. For example, it is typically used as supportive care for patients requiring enhanced neuronal integrity. As a choline donor, the drug’s general purpose is to assist in the preservation and structural repair of neuronal tissue, supporting overall cognitive and neurological health. Pharmacological studies consistently support its role in helping brain cells maintain their structure, particularly when under metabolic stress.

What side effects are possible with Cicolin?

Possible Side Effects and Safety Information

The safety profile of Cicolin (and related substances like Citicoline) is generally considered favorable in medical literature. However, regulatory documents highlight several areas of caution related to different formulations and drug classes associated with the name.

Documented Adverse Reactions

Adverse effects noted in regulatory sources are generally associated with specific drug formulations (e.g., Cyclobenzaprine hydrochloride) and involve the Central Nervous System (CNS) or hypersensitivity reactions.

System-Organ Class Key Adverse Reactions
Central Nervous System Drowsiness, fatigue, headache, dizziness, impairment of mental and/or physical abilities, tremors, agitation, hallucinations.
Gastrointestinal Dry mouth, upset stomach, nausea, constipation, vomiting.
Cardiovascular Fast or irregular heartbeats.
Allergic/Hypersensitivity Allergic reactions requiring emergency equipment and personnel (e.g., hives, swelling of the face, difficult breathing).

Serious Adverse Reactions and Safety Restrictions

Serious reactions associated with related drug classes include Serotonin Syndrome (symptoms like agitation, fast heart rate, and loss of coordination), which requires immediate medical attention, and Neuromuscular Blockade (e.g., apnea) in patients with impaired renal function.

Restrictions and Cautions:

  • Impairment of Abilities: Due to the potential for impaired mental and/or physical abilities, operating machinery or driving a motor vehicle should be avoided, especially when Cicolin (or related substances) is used concomitantly with alcohol or other CNS depressants.
  • Population Risk: Increased frequency and severity of certain adverse events, including serious side effects, are more likely in older adults. Dosage adjustments may be necessary in this population.
  • Concomitant Use: Use with other CNS depressants or MAO inhibitors may be contraindicated or increase the risk of serious complications like Serotonin Syndrome. Consult with a healthcare provider regarding all concurrent medications.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies the overdose profile of Cicolin (Citicoline) as one of very low toxicity in humans. This classification is supported by clinical data which indicates the substance has been observed to be safe at doses up to 2 g/day, and regulatory summaries often state that the appearance of severe intoxication is unlikely even with accidental over-ingestion.

No specific severe or life-threatening outcomes resulting directly from Cicolin overdose are explicitly documented in the official prescribing information. The most specific clinical presentation noted at high dose is the occurrence of transient headaches. Furthermore, no changes or abnormalities were documented in hematology, clinical biochemistry, or neurological tests following high dose exposure in controlled studies. No population-specific overdose considerations are currently detailed in regulatory documents.

In the event of over-ingestion, the official guidance for management is defined as symptomatic therapy. No specific antidote is mentioned in the official regulatory overdose sections reviewed. Despite the low toxicity profile, the immediate action mandated by regulators is to seek emergency medical treatment or contact a healthcare professional immediately for any suspected overdose event.

Therapeutic Uses of Cicolin

The use of Cicolin (Citicoline) is applied across domains where additional symptomatic support is needed. The substance is commonly used to help with cognitive function and may assist with sustained attention.

Cicolin is generally applied in clinical settings that involve acute neurological events, such as an ischemic stroke or a traumatic brain injury (TBI). It may assist with managing resulting functional and neurological deficits, particularly when symptoms become more noticeable. The supportive benefit assists with maintaining functional stability and contributes to easing the overall symptom load.

The medication is relevant for conditions characterized by periods of heightened symptoms related to cognitive impairment and memory loss, including symptoms associated with vascular decline. It is considered relevant when groups of symptoms involve difficulty with attention, focus, and executive functions. This supportive relief may help patients cope more steadily with symptom fluctuations when cognitive symptoms are more noticeable.


Quick Fact: Relief for Cognitive Strain

Cicolin is considered relevant across domains where additional symptomatic support is needed, including conditions involving acute neurological injury, chronic cerebrovascular decline, and deficits in attention and mental performance.

Regulatory References

  1. Health Canada Product Information

Eligibility and Restrictions for Use

The official regulatory profile for Cicolin specifies strict limitations regarding who can and cannot use the medicine, based on regulatory labeling for its active component, Citicoline.


Eligibility Scope

Populations for whom use is Contraindicated (Absolute Ban):

  • Patients with known hypersensitivity or allergy to the active substance or any other component of the formulation.
  • Patients presenting with hypertonia of the parasympathetic nervous system.

Populations for whom use is Restricted or Not Recommended:

Population Group Eligibility Status
Pregnancy Conditional Use: Only when the expected benefit for the mother is judged to definitively outweigh potential risks to the fetus.
Breastfeeding Conditional Use: Only when the expected benefit for the mother is judged to definitively outweigh potential risks to the baby.
Children Use Not Established: Prescribing is limited and only permitted when the benefits are considered to outweigh the risks due to insufficient clinical data.
Persistent Intracranial Hemorrhage Use with Caution: Requires very slow administration, as larger doses may increase cerebral blood flow.

These eligibility constraints define the patient populations for whom the medicine is either absolutely forbidden or requires specific caution and medical justification before use, based on governmental standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Cicolin (Citicoline) as stated in government regulatory documents.


Documented Interaction Patterns

The interaction profile of Cicolin is primarily defined by specific restrictions and a pharmacodynamic potentiation effect. No interactions mediated by cytochrome P450 enzymes (CYP inhibition or induction) or drug transporters are documented in official prescribing information.

Interaction Type Interacting Substance Official Regulatory Statement
Formal Contraindication Meclofenoxate (Clophenoxate) Co-administration is explicitly contraindicated and must be avoided.
Pharmacodynamic Potentiation L-dopa (Levodopa) Citicoline officially potentiates the effects of L-dopa.
Mandatory Substance Restriction Alcohol Must not be consumed during the period of treatment.

Regulatory Summary

The official regulatory documents establish two mandatory constraints: the prohibition of co-administration with Meclofenoxate and the strict restriction on alcohol consumption. The profile also formally documents the potentiation of effects when Cicolin is co-administered with L-dopa. These statements represent the key interaction-related requirements and constraints defined by authoritative health agencies.

Mechanism of Action

Citicoline (Cicolin) functions through a dual mechanistic action involving membrane phospholipid synthesis and neurotransmitter precursor donation, which provides metabolic precursors for the maintenance of neuronal systems.

Neuronal Membrane Synthesis and Stabilization

This mechanism involves Citicoline's metabolites acting as precursors for the de novo synthesis of essential cell wall phospholipids, particularly Phosphatidylcholine ( PtdCho). By supplying these building blocks via the Kennedy pathway, the molecule facilitates the structural incorporation of phospholipids into neuronal and mitochondrial membranes. This process also functionally attenuates the activity of the enzyme Phospholipase A2 ( PLA2), preventing destructive membrane breakdown that occurs during metabolic stress and contributes to maintaining cell viability by reducing membrane catabolism.

Neurotransmitter Precursor Donation and Metabolic Modulation

The choline moiety acts as a vital precursor, driving the synthesis of the neurotransmitter Acetylcholine, which is involved in cholinergic communication and signaling. Concurrently, Citicoline modulates the synthesis and release of central monoamines like Dopamine. Furthermore, its mechanisms extend to safeguarding the cell’s energy production by protecting mitochondrial components and restoring key enzymes like the Na^+/ K^+ ATPase, influencing cellular bioenergetics and modulating systems associated with neuronal viability.

Dosage and Administration Information

How to Use Cicolin: Official Administration Guidelines

Cicolin (Citicoline) is administered according to standard dosage regimens and routes. This section details the official, high-level instructions for its use, excluding safety, therapeutic claims, and clinical decision-making.


Administration Scope

Entity Detail
Route of Administration The medication is approved for Oral intake (tablet or solution) and Parenteral administration via Intramuscular (IM) or Intravenous (IV) injection.
Dosing Schedule The standard adult daily dose is within the range of 500 mg to 2000 mg, with the maximum daily intake strictly limited to 2000 mg (2 g) total.
Timing in relation to Meals Oral forms of Cicolin can be taken with food or between meals.
Age-Group Administration Older adults (Elderly) do not require dose adjustment based on age.
Special Procedural Conditions Intravenous injection must be administered slowly, over a duration of 3 to 5 minutes, or via IV drip/infusion. The drug must not be co-administered with preparations containing meclofenoxate.

Official Procedural Structure

The formal usage protocol for Cicolin defines the dosage as individualized based on the patient’s clinical course and condition, not based on a single fixed regimen. The medication is typically administered in a daily frequency (once or twice daily). The overall length of the treatment course is determined by ongoing assessment, which establishes the individualized duration. For parenteral use, the administration technique is procedural, requiring careful attention to the slow rate of infusion or injection.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cicolin

The research on Cicolin (Citicoline) has been conducted to explore its role in several neurological contexts. This summary focuses on the types of evidence available and what the studies have observed, without providing clinical advice or treatment recommendations.


Evidence for Use in Acute Ischemic Stroke

Studies have explored Cicolin’s application in research examining acute ischemic stroke, typically initiated within the first three days following symptom onset. Researchers primarily used Randomized Controlled Trials (RCTs) and pooled data analyses that examined the measured outcomes of Cicolin on functional recovery, neurological status, and independence measurements. Findings describe patterns observed in the studies concerning functional recovery at 90 days. However, the pooled data analyses reported mixed or inconsistent findings regarding functional recovery measurements, particularly when comparing results from older trials with the largest, modern trials. Certainty remains low due to inconsistent findings and research provides insufficient data regarding the outcomes when the compound was used concurrently with current standard stroke treatments like thrombolysis.


Evidence for Chronic Cognitive Decline

Cicolin was studied for conditions of vascular decline and memory loss, including Vascular Cognitive Impairment (VCI). Studies, mainly RCTs, typically spanned several months and research examined scores related to global cognitive status and specific cognitive abilities. Findings in some studies described measurements of change in specific cognitive domains, such as sustained attention. The evidence in this area is characterized by the fact that many of the available studies have smaller sample sizes. The follow-up durations were limited primarily to short-to-intermediate timeframes, and consequently, the long-term effects are not fully established.


Evidence Gaps and Areas of Uncertainty

The most notable research gap is the inconsistency of findings across RCTs in acute stroke and Traumatic Brain Injury (TBI). The follow-up durations were limited across most major studies, meaning there is limited information for long-term outcomes and the stability of any measured effects. Data for certain groups remain insufficient, particularly for populations like children or women who are pregnant, as they are typically excluded from major neurological RCTs. The evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Citicoline (N06BX06): WHO Collaborating Centre for Drug Statistics Methodology, ATC Classification Index

Frequently Asked Questions (FAQ)

Common questions about Cicolin (FAQ)

Q: What is the main purpose of Cicolin?

Official documents indicate that Cicolin is approved for the management of patients who have suffered serious brain injuries that are either traumatic or vascular (related to blood vessels). It is also used in cases involving degenerative changes and chronic vascular injuries associated with senile dementia. The official indication describes the condition the medicine is approved to manage.

Q: What class of medication does Cicolin belong to?

Cicolin, known scientifically as Citicoline, is primarily described as a chemical intermediate necessary for creating crucial components of cell membranes in the brain. Due to its impact on brain function and metabolism, it is also referenced in some medical literature as a nootropic agent.

Q: What are the most frequently reported side effects of Cicolin?

Official product information lists several possible side effects. Some of the reported effects include feelings of anxiety, dizziness, or headache, as well as issues like insomnia (difficulty sleeping) and constipation or nausea. Serious side effects are generally considered rare.

Q: Does taking Cicolin typically cause weight changes?

Regulatory summaries indicate that changes in appetite and body weight are not among the most common adverse events. However, increased appetite leading to weight gain is listed as one of the non-frequently reported side effects in some authoritative medical sources.

Q: Can Cicolin affect sleep patterns or cause insomnia?

Yes, according to the official patient information leaflet, insomnia, or difficulty falling or staying asleep, is a possible adverse effect. Insomnia is described as one of the recognized side effects of the medication.

Q: What are the known long-term health risks associated with Cicolin use?

The evidence from clinical use reports indicate that the medication exhibits a low toxicity profile. It has been studied and observed to be well-tolerated when used at typical doses for the established duration of treatment in various trials.

Q: Can Cicolin cause a skin rash or a potential allergic reaction?

The medicine is contraindicated (officially prohibited) if a patient has an allergy to Citicoline or its components. Additionally, some specific formulations contain ingredients like sulfites, which are officially noted to cause allergic-type reactions in certain sensitive individuals.

Q: Is nausea or stomach upset an expected side effect when starting Cicolin?

Gastrointestinal issues are among the possible side effects listed in the official documents. These include nausea and stomach pain, and sometimes anorexia (loss of appetite). These are considered possible effects associated with the medicine.

Q: Is it safe to take Cicolin with certain blood pressure medications?

Official regulatory information indicates that hypotension (low blood pressure) is a possible side effect of Cicolin. This means that co-administration with other agents that also affect blood pressure levels may require monitoring.

Q: What are the general categories of medicines that might interact with Cicolin?

The official product information specifies a contraindication with medicines containing meclofenoxate (Centrophenoxine) and caution is described for medicines such as Levodopa. The regulatory focus is on drugs that work on similar pathways in the brain.

Q: If a dose of Cicolin is missed, how does that affect the overall course of treatment?

The official patient information states that a double dose must not be taken to make up for one that was forgotten. The instruction is to continue the treatment schedule as planned by simply taking the next scheduled dose when it is due.

Q: How is Cicolin processed or broken down by the body?

When Cicolin is administered, it is broken down, or metabolized, primarily in the gut wall and the liver into two major components: choline and cytidine. These components are then distributed throughout the body and are able to pass into the brain where they are re-used.

Q: Is Cicolin safe to use during pregnancy?

Due to the lack of sufficient reliable safety data for use in this population, Cicolin is generally avoided during pregnancy. Official patient information states that consultation with a prescribing professional is required regarding its use during this period.

Q: Can Cicolin be used while breastfeeding?

Official warnings indicate that there is not enough reliable information available to confirm whether Cicolin passes into breast milk or its safety for a nursing infant. Due to the lack of sufficient data, avoidance of the medicine is generally described in official guidance.

Q: Are there any age restrictions for people who can take Cicolin?

The official prescribing information focuses mostly on dosing and use in adults and adolescents. Because the necessary data for widespread use in very young children is often not clearly defined in patient information leaflets, this is often interpreted as limited data availability for younger age groups.

Q: Can elderly patients use Cicolin without additional safety concerns?

Older adults generally do not require a dose change based on age alone. However, official guidelines state that if an elderly patient has diminished renal function (reduced kidney function), a dosage adjustment is required. This indicates an additional safety consideration for that sub-group.

Q: Is Cicolin safe for people with kidney disease?

Cicolin is contraindicated for patients who have had serious kidney problems. If kidney function is compromised, a dosage adjustment may be required, and monitoring may be necessary.

Q: What are the main warnings or precautions officially listed for Cicolin?

Official precautions list conditions for which Cicolin is contraindicated (prohibited). These include being allergic to any ingredient, having serious kidney problems, being hypertonic, or having persistent intracranial hemorrhage (bleeding in the brain).

Q: What does the research evidence indicate about the efficacy of Cicolin?

Official regulatory documents confirm that Cicolin has been subjected to clinical investigations related to its use in conditions such as stroke, brain injury, and cognitive deficits. The evidence supporting the medicine’s action is reflected by its official approvals and indications in different countries.

Q: Does Cicolin affect the ability to drive or operate machinery?

The patient information leaflet explicitly contains a warning stating that patients must not operate heavy machinery or automobiles while using the medicine, due to potential effects on concentration.

Q: How should Cicolin be stored at home to keep it effective?

To maintain effectiveness, Cicolin should be kept in a cool, dry place protected from direct light. Official storage guidelines specify keeping the medicine at temperatures not exceeding 30 C and ensuring it is always kept out of the sight and reach of children.

Q: What is the half-life of Cicolin in the body?

Cicolin is eliminated from the body in a two-phase process. Official documents indicate two different elimination half-lives: approximately 56 hours for the portion removed through breathing ( CO2) and 71 hours for the portion removed through urine.

How should Cicolin be stored and disposed of?

How to Store and Dispose of Cicolin?

Official regulatory documents define strict requirements for storing and disposing of Cicolin (Citicoline) preparations to maintain efficacy and ensure safety.


Storage Requirements

  • Temperature: Cicolin must be stored at controlled room temperature, typically not exceeding 30 C.
  • Protection: The medicine must be protected from light and stored away from excessive moisture.
  • Packaging: Keep the medicine in its original container and ensure the container remains tightly closed.
  • Child Safety: All product labels mandate that Cicolin must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Cicolin must not be thrown away in household waste or flushed down the toilet. Disposal must follow procedures to protect the environment. Individuals are instructed to return the medicine to a pharmacist or utilize an approved drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cicolin found in:

A-Z Index: